CLiMB Study Published in the Journal of Hepatology
Our landmark liver cancer detection study is now peer-reviewed and published.
Read More
Helio Genomics is on a mission to make cancer detection simple, affordable, and early, when it is most treatable. With a single blood draw, we help more people find cancer at the stage they are most likely to beat it.
For most cancers, 90% of people survive when the disease is found early. Yet too many of today's tests are inconvenient, costly, and poor at catching cancer in time, so too many people are diagnosed when it is already too late.
Helio Genomics exists to change that. We focus on early detection, when treatment works best, and the chance of beating cancer is highest.
At the heart of Helio Genomics is an epigenomic, blood-based platform powered by artificial intelligence. It reads the cfDNA methylation patterns that reveal cancer early, and it is built to do more than find one disease. It is designed to change how cancer is detected and monitored across the whole patient journey.
We read proprietary epigenomic signatures, patterns of DNA methylation, that can reveal cancer as early as Stage I from a single blood draw, when treatment works best.
Beyond detection, our platform is designed to monitor minimal residual disease, helping clinicians track response and guide decisions over time.
Machine learning turns complex biomarker data into clear, reliable answers, built on proprietary, patented science developed over nearly a decade.
HelioLiver LDT is the first test built on the Helio platform, and it is available for clinical use today. It is a simple blood test for the early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. In the CLiMB trial, HelioLiver detected Stage I liver cancer four times more often than ultrasound, the current standard of care.
Since 2016, Helio Genomics has pioneered the use of DNA methylation for early cancer detection — with foundational research published in some of the world's most respected scientific journals.
Founded with a proprietary, patented methylation profile of novel cancer biomarkers
Early methylation detection research published in Nature Materials and PNAS
An AI and machine learning detection method was published in Nature Communications
CLiMB trial results published in the Journal of Hepatology
When cancer is caught early, while it is still localised, survival rates are far higher, and many more treatment options are open. Closing the gap between late and early diagnosis, beginning with the liver, is the heart of what we do.
Bringing groundbreaking cancer detection to patients takes partnership. Helio Genomics works alongside leading healthcare and technology organisations to expand access to early testing, including clinical availability through Quest Diagnostics, one of the largest diagnostic networks in the United States, and a strategic commercial partnership with Syneos Health.
Bring earlier cancer detection into your practice with a simple blood draw.
For ProvidersIf you are at higher risk for liver cancer, learn how a simple blood test could help find it earlier.
For PatientsExplore the platform, the science, and the momentum behind Helio Genomics.
Investor RelationsOur landmark liver cancer detection study is now peer-reviewed and published.
Read MoreA strategic commercial partnership to accelerate national adoption of HelioLiver.
Read MoreDr. Bharat Tewarie on where the company and the field are headed.
Watch the InterviewFrom our first test to our next, Helio Genomics is building the future of early cancer detection one blood draw at a time.